Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CARIS LIFE SCIENCES INC (CAI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$26.03-21.64%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.34 → 0.35 EPS · FY ending Dec 31, 2027 · 8 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CAI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Clinical therapy selection volume growth of 20% in 2026 | Clinical therapy volume should grow about 20% this year. | Intact | clinical therapy volume growth falls below 15% in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-growth healthcare business, with recent financial performance described as strong and the sector backdrop supportive. The long-term thesis is intact and has shifted from mixed to mildly favorable, though risk remains elevated.
Valuation is stretched, with CAI carrying a modest premium versus peers and expectations broadly aligned with the model. That leaves the expectations gap relatively narrow, so the market appears to require continued delivery rather than a major change in the business outlook.
Near-term execution is tracking management’s priorities: 2026 revenue guidance was raised, clinical therapy selections are growing, and molecular profiling revenue and case volume are expanding. The next results remain a risk because recent earnings surprises have been erratic, and a guidance reversal would damage credibility.
Over the multi-year view, the thesis hinges on sustaining revenue and case-volume growth while meeting the raised 2026 guidance. A guidance cut or further weakening in jobs data could weigh on confidence, while continued strong results and guidance from healthcare peers would support the sector backdrop.
CAI’s growth story remains intact, but stretched expectations and elevated near-term execution risk make consistent delivery the key test over the next 1 to 3 years. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in CARIS LIFE SCIENCES INC's published investment case. The stated target is positive EPS by end of 2027. |
| Improving |
| EPS remains negative through 2027 |
Diluted EPS: $0.05 per share FY2026-Q3; GAAP. Published target: positive EPS by end of 2027. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20260.05 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve $1.0B to $1.02B revenue in 2026 | A primary condition in CARIS LIFE SCIENCES INC's published investment case. The stated target is >= $1.0B revenue. | Intact | annual revenue falls below $1.0B in 2026 | Revenue: $275.358M FY2026-Q3; GAAP. Published target: >= $1.0B revenue. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026275,358,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.36 → $0.35 · observed estimates
$1.20B → $1.23B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-25 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-26 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-27 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-28 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-29 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-30 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-07-31 | $0.35 | $1,197,076,592 | 8 / 9 |
| 2026-08-01 | $0.35 | $1,197,076,592 | 8 / 9 |
| 2026-08-02 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-08-03 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-08-04 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-08-05 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-08-06 | $0.36 | $1,198,244,300 | 10 / 13 |
| 2026-08-07 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-08 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-09 | $0.37 | $1,208,738,540 | 10 / 13 |
| 2026-08-10 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-11 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-12 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-13 | $0.38 | $1,215,790,080 | 10 / 13 |
| 2026-08-14 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-15 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-16 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-17 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-18 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-19 | $0.35 | $1,207,588,663 | 8 / 9 |
| 2026-08-20 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-21 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-22 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-23 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-24 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-25 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-26 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-27 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-28 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-29 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-30 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-08-31 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-01 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-02 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-03 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-04 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-05 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-06 | $0.35 | $1,215,794,049 | 8 / 9 |
| 2026-09-07 | $0.35 | $1,215,794,049 | 7 / 9 |
| 2026-09-08 | $0.35 | $1,215,794,049 | 7 / 9 |
| 2026-09-09 | $0.35 | $1,215,794,049 | 7 / 9 |
| 2026-09-10 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-11 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-12 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-13 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-14 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-15 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-16 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-17 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-18 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-19 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-20 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-21 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-22 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-23 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-24 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-25 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-26 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-27 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-28 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-29 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-09-30 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-10-01 | $0.35 | $1,215,248,718 | 8 / 10 |
| 2026-10-02 | $0.34 | $1,215,248,718 | 8 / 10 |
| 2026-10-03 | $0.34 | $1,215,248,718 | 8 / 10 |
| 2026-10-04 | $0.34 | $1,215,248,718 | 8 / 10 |
| 2026-10-05 | $0.34 | $1,215,248,718 | 8 / 10 |
| 2026-10-06 | $0.34 | $1,220,534,432 | 8 / 10 |
| 2026-10-07 | $0.34 | $1,220,534,432 | 8 / 10 |
| 2026-10-08 | $0.35 | $1,225,586,643 | 8 / 10 |
| 2026-10-09 | $0.35 | $1,225,586,643 | 8 / 10 |
| 2026-10-10 | $0.35 | $1,225,586,643 | 8 / 10 |
| 2026-10-11 | $0.35 | $1,227,179,379 | 8 / 10 |
| 2026-10-12 | $0.35 | $1,227,179,379 | 8 / 10 |
| 2026-10-13 | $0.35 | $1,227,179,379 | 8 / 10 |
| 2026-10-14 | $0.35 | $1,227,750,808 | 8 / 10 |
| 2026-10-15 | $0.35 | $1,227,750,808 | 8 / 10 |
| 2026-10-16 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-17 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-18 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-19 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-20 | $0.35 | $1,228,463,752 | 8 / 10 |
| 2026-10-21 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-22 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-23 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-24 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-25 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-26 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-27 | $0.35 | $1,228,463,294 | 8 / 10 |
| 2026-10-28 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-10-29 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-10-30 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-10-31 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-11-01 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-11-02 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-11-03 | $0.35 | $1,228,463,623 | 8 / 10 |
| 2026-11-04 | $0.35 | $1,228,463,623 | 8 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 4 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.